Antibody-Drug Conjugates The 21st Century Magic Bullets for Cancer

Master the Science of Antibody-Drug Conjugates (ADCs)

This authoritative volume provides a holistic and systematic picture of antibody-drug conjugates (ADCs), from their foundational concepts to their future applications. It serves as a practical resource for scientists, professors, and students who want to expand their knowledge of this cutting-edge field.

Key Features

• Comprehensive Coverage: The book is divided into six sections, covering the ADC construct, development issues, intellectual property (IP), pharmacoeconomics, and future directions.
• In-Depth Analysis: It examines every aspect of ADC design, including the selection of the antibody, the drug, and the linker. It also discusses developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges.
• Case Studies: Case studies are presented for three FDA-approved ADCs—gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®)—as well as a late-stage clinical trial ADC, glembatumumab vedotin (CDX-011).
• Forward-Looking Perspective: The volume concludes with a perspective from the editors on the future directions of ADC development and their clinical applications.